期刊文献+

多发性骨髓瘤糖皮质激素受体研究进展 被引量:1

原文传递
导出
摘要 糖皮质激素是多发性骨髓瘤联合化疗的主要药物,通过与糖皮质激素受体持异结合抑制骨髓瘤细胞增殖,对糖皮质激素耐药的骨髓瘤细胞不仅糖皮质激素受体数量减少,而且功能异常。
作者 吕鸣
机构地区 上海长征医院
出处 《国外医学(生理病理科学与临床分册)》 北大核心 1996年第2期94-97,共4页 Foreign Medical Sciences(Pathophysiology and Clinical Medicine)
  • 相关文献

同被引文献7

  • 1Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents [ J ]. N Engl J Med, 1984,310:1353-1356.
  • 2Alexandrakis MG, Passam FH, Sfiridaki K,et al. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival [ J ]. Leuk Res,2004,28 ( 3 ) :259-266.
  • 3Eucker J, Eikel D, Heider U, et al. Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion [ J ]. Anticancer Drugs,2003,14 ( 10 ): 793-799.
  • 4Pandit SR, Vesole DH. Management of renal dysfunction in multiple myeloma[ J ]. Curr Treat Options Oncol,2003,4 (3) :239-246.
  • 5Weber DM. Newly diagnosed multiple myeloma [ J]. Curr Treat Options Oncol,2002,3( 3 ) :235-245.
  • 6Ossenkoppele GJ. Treatment of multiple myeloma in elderly patients. New developments [ J ]. Drugs Aging, 1997,11 ( 2 ): 152-164.
  • 7Tribalto M, Amadori S, Cudillo L, et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myloma: an Italian Multicenter Study [ J ]. Haematologica,2000,85( 1 ) :52-58.

引证文献1

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部